These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 15058645

  • 1. Maximum tolerable dose of cyclophosphamide and azathioprine in Pakistani patients with primary renal disease.
    Ali SS, Rabbani MA, Moinuddin SS, Virani S, Farooque F, Salam A, Ahmad A.
    J Pak Med Assoc; 2004 Jan; 54(1):39-42. PubMed ID: 15058645
    [Abstract] [Full Text] [Related]

  • 2. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide.
    Benenson E, Fries JW, Heilig B, Pollok M, Rubbert A.
    Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 4. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC, Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement.
    Gottenberg JE, Mahr A, Pagnoux C, Cohen P, Mouthon L, Guillevin L, French Vasculitis Study Group (FVSG).
    Presse Med; 2007 May; 36(5 Pt 1):771-8. PubMed ID: 17416480
    [Abstract] [Full Text] [Related]

  • 6. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
    Mok CC, Ho CT, Chan KW, Lau CS, Wong RW.
    Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978
    [Abstract] [Full Text] [Related]

  • 7. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 8. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
    Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A.
    Int Urol Nephrol; 2009 Dec; 41(1):153-61. PubMed ID: 18214709
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Berden JH, Dutch Working Party on systemic lupus erythematosus.
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 12. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
    Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC.
    Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
    [Abstract] [Full Text] [Related]

  • 13. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC, Chan PT, To CH.
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [Abstract] [Full Text] [Related]

  • 14. Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.
    Cimé-Aké E, Barrera-Vargas A, Demichelis-Gómez R, Ramírez-Alemón M, Rull-Gabayet M.
    Clin Rheumatol; 2024 Aug; 43(8):2521-2532. PubMed ID: 38916764
    [Abstract] [Full Text] [Related]

  • 15. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
    Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schlüter B, Jacobi AM.
    Arthritis Res Ther; 2015 Apr 03; 17(1):92. PubMed ID: 25890338
    [Abstract] [Full Text] [Related]

  • 17. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.
    Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP.
    J Rheumatol; 2009 Jan 03; 36(1):89-95. PubMed ID: 19040311
    [Abstract] [Full Text] [Related]

  • 18. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
    Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, Spiera RF, Davis JC, McCune WJ, Ytterberg SR, St Clair EW, Allen NB, Specks U, Stone JH, WGET Research Group.
    Arthritis Care Res (Hoboken); 2011 Dec 03; 63(12):1777-81. PubMed ID: 22127969
    [Abstract] [Full Text] [Related]

  • 19. [Pulsed doses of cyclophosphamide in the treatment of Wegener's granulomatosis].
    Kovacević Z, Mitrović D, Tomić I, Jovanović D, Skatarić V, Dimitrijević J, Rabrenović V, Trifunović G.
    Vojnosanit Pregl; 1999 Dec 03; 56(1):31-7. PubMed ID: 10230331
    [Abstract] [Full Text] [Related]

  • 20. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.
    Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, Roberson G, Langford CA, Hoffman GS.
    Medicine (Baltimore); 2007 Sep 03; 86(5):269-277. PubMed ID: 17873756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.